Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor | Zendy

Hilary Longhurst | Zendy; Marco Cicardi | Zendy; Timothy Craig | Zendy; Konrad Bork | Zendy; Clive Grattan | Zendy; James Baker | Zendy; Henry Li | Zendy; Avner Reshef | Zendy; James R. Bonner | Zendy; Jonathan A. Bernstein | Zendy; John Anderson | Zendy; William Lumry | Zendy; Henriette Farkas | Zendy; Constance H. Katelaris | Zendy; Gordon Sussman | Zendy; Joshua Jacobs | Zendy; Marc A. Riedl | Zendy; Michael Manning | Zendy; Jacques Hébert | Zendy; Paul K. Keith | Zendy; Shmuel Kivity | Zendy; Sergio Neri | Zendy; Donald S. Levy | Zendy; M. L. Baeza | Zendy; Robert Nathan | Zendy; Lawrence B. Schwartz | Zendy; Teresa Caballero | Zendy; William H. Yang | Zendy; Ioana Crisan | Zendy; Dolores Hernández Fernández de Rojas | Zendy; Iftikhar Hussain | Zendy; Michael Tarzi | Zendy; Bruce Ritchie | Zendy; Pavlína Králíčková | Zendy; Mar Guilarte | Zendy; Syed M. Rehman | Zendy; Aleena Banerji | Zendy; Richard Gower | Zendy; Debra M. Bensen-Kennedy | Zendy; Jonathan M. Edelman | Zendy; Henrike Feuersenger | Zendy; JohnPhilip Lawo | Zendy; Thomas Machnig | Zendy; Dipti Pawaskar | Zendy; Ingo Pragst | Zendy; Bruce L. Zuraw | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor

Author(s) -

Hilary Longhurst,

Marco Cicardi,

Timothy Craig,

Konrad Bork,

Clive Grattan,

James Baker,

Henry Li,

Avner Reshef,

James R. Bonner,

Jonathan A. Bernstein,

John Anderson,

William Lumry,

Henriette Farkas,

Constance H. Katelaris,

Gordon Sussman,

Joshua Jacobs,

Marc A. Riedl,

Michael Manning,

Jacques Hébert,

Paul K. Keith,

Shmuel Kivity,

Sergio Neri,

Donald S. Levy,

M. L. Baeza,

Robert Nathan,

Lawrence B. Schwartz,

Teresa Caballero,

William H. Yang,

Ioana Crisan,

Dolores Hernández Fernández de Rojas,

Iftikhar Hussain,

Michael Tarzi,

Bruce Ritchie,

Pavlína Králíčková,

Mar Guilarte,

Syed M. Rehman,

Aleena Banerji,

Richard Gower,

Debra M. Bensen-Kennedy,

Jonathan M. Edelman,

Henrike Feuersenger,

JohnPhilip Lawo,

Thomas Machnig,

Dipti Pawaskar,

Ingo Pragst,

Bruce L. Zuraw

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1613627

Subject(s) - medicine , hereditary angioedema , angioedema , c1 inhibitor , dermatology , medline , political science , law

Hereditary angioedema is a disabling, potentially fatal condition caused by deficiency (type I) or dysfunction (type II) of the C1 inhibitor protein. In a phase 2 trial, the use of CSL830, a nanofiltered C1 inhibitor preparation that is suitable for subcutaneous injection, resulted in functional levels of C1 inhibitor activity that would be expected to provide effective prophylaxis of attacks.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research